| | |

AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising

AHRP Position Statement on Mental Health Screening – FDA Hearing Re: Drug Advertising Wed, 02 Nov 2005 FDA is holding public hearings (Nov 1, 2) Re:  Direct-to-Consumer Promotion of Medical Products at: National Transportation Safety Board Boardroom and Conference Center 429 L’Enfant Plaza, SW., Washington, DC 2 Time: 9:00 –5:00….

AHRP in the News

Alliance for Human Research Protection in the Press Feb 17, 2005: FDA Critics Slam Plan for Safety Reform – Nature “This is smoke and mirrors and musical chairs,” says Vera Sharav, president of the New York-based Alliance for Human Research Protection. “They will be using the very same officials that…

Leading Antipsychotic Drugs Come Under New Scrutiny – NYT

Leading Antipsychotic Drugs Come Under New Scrutiny – NYT Tuesday, May 20, 2003 A front page article in The New York Times reveals that the pillars of American psychiatry–including Dr. Jeffrey Lieberman, Dr. John Kane, Dr. William Carpenter–are acknowledging that evidence is lacking to support the claims that the new…

The Facts about Medicare "Wider Choices in Drug Benefits"

The Facts about Medicare “Wider Choices in Drug Benefits" Thu, June 16, 2005 The New York Times reports: “The expansion of Medicare to cover prescription drugs is President Bush’s most significant achievement in domestic policy. He plans to emphasize it at two events this week, on Thursday in Washington and…

Screening for Mental Illness–A Diabolical, Profit-Enhancing Experiment

Screening for Mental Illness–A Diabolical, Profit-Enhancing Experiment Fri, 22 Oct 2004 Concerned citizen groups are joining our effort to stop the government from implementing a sweeping recommendation for lifetime screening for mental illness. If implemented, the first to be screened for hidden mental illness are America’s 52 million school children…

$95 billion a year spent on medical research in US – JAMA

$95 billion a year spent on medical research in US – JAMA Fri, 23 Sep 2005 A special issue of the Journal of the American Medical Association, JAMA, focuses on medical research spending and findings. A study that examined US spending for medical research—$95 billion approaching $100 billion–57% is spent…

AHRP Files Court Brief to Protect Children from Harmful Research

October 1, 2001 Text of AHRP Amicus Brief filed with the Maryland Court of Appeals in support of the Court’s ruling against Kennedy Krieger Institute for exposing children to lead poison in an experiment. The Court of Appeals Decision Validates AHRP’s Stand Against Using Children in Harmful Research Experiments. ___________________________________________________…

Cost and Consequence: drug "cocktails" deplete Medicaid_Globe

Cost and Consequence: drug “cocktails” deplete Medicaid_Globe Tue, 24 Jun 2003 The escalating cost of healthcare is in large measure due tothe spiraling expenditure on drugs–many of which are misprescribed.The Boston Globe reports about one Medicaid patient who is prescribed18 medications at a cost of roughly $16,000 a year–“all at…

40 Psychiatrists Lobby FDA to Legitimize Drug Restraints for Aggression

40 Psychiatrists Lobby FDA to Legitimize Drug Restraints for Aggression Mon, 21 Mar 2005 At first glance, a Newsday article–Hot Under the Collar?– might appear as a hilarious parody of bio-psychiatry. It is not. “Recently, 40 scientists met with two FDA officials to make a case for testing treatments specifically…

How Health Care in America Became Big Business–And Bad Medicine – OpEd NYT – Zoloft NYT Ad Fails to Disclose Suicide risk

How Health Care in America Became Big Business–And Bad Medicine – OpEd NYT Zoloft NYT Ad Fails to Disclose Suicide risk Mon, 25 Oct 2004 An Op-Ed in Sunday’ New York Times by Time magazine editors, Donald Barlett and James Steele, is a MUST READ assessment of what ails America’s…

FDA: Regulatory Protections for Children. Comments by Sharav, Noble, & Fishman for AHRP

FDA: regulatory protections for children. Comments submitted by Vera Hassner Sharav, John H. Noble, Jr., Ph.D and Howard Fishman, MEd, MSW for AHRP August 6, 2001 To: Dr. Bernard Schwetz Acting Commissioner Food and Drug Administration Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville,…